SCHEMBL2748040

SCHEMBL2748040

CNC(=O)c1cc(Oc2ccc3c(C(=O)Nc4ccc(Cl)c(C(F)(F)F)c4)cccc3c2)ccn1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 9/20 0.75
RET P07949 3/20 0.71
RAF1 P04049 13/20 0.71
BRAF P15056 9/20 0.71
FLT1 P17948 3/20 0.71
FLT4 P35916 3/20 0.71
RIPK2 O43353 2/20 0.71
ABCB11 O95342 2/20 0.71
ABL1 P00519 2/20 0.71
HTR1A P08908 2/20 0.71
PDGFRB P09619 2/20 0.71
ADORA3 P0DMS8 2/20 0.71
KIT P10721 2/20 0.71
FGFR1 P11362 2/20 0.71
PDGFRA P16234 2/20 0.71
MAOA P21397 2/20 0.71
EPHA1 P21709 2/20 0.71
TBXA2R P21731 2/20 0.71
EPHA2 P29317 2/20 0.71
TTK P33981 2/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4548904 0.89 KDR (0.75) KDRRETRAF1BRAFFLT1
SCHEMBL2747491 0.87 KDR (0.78) KDRRETRAF1BRAFFLT1
SCHEMBL4548992 0.87 KDR (0.72) KDRRETRAF1BRAFFLT1
SCHEMBL2746145 0.86 KDR (0.80) KDRRETRAF1BRAFFLT1
SCHEMBL2437469 0.86 KDR (0.71) KDRRETRAF1BRAFFLT1
SCHEMBL2747600 0.86 KDR (1.00) KDRRAF1BRAFFLT1FLT4
SCHEMBL2747900 0.85 KDR (0.78) KDRRETRAF1BRAFFLT1
SCHEMBL2747739 0.85 KDR (0.84) KDRRETBRAFFLT1FLT4
SCHEMBL2748188 0.85 KDR (0.81) KDRBRAFFLT1FLT4FGFR1
SCHEMBL2747529 0.84 KDR (0.80) KDRRETBRAFFLT1FLT4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178557-B2 Compounds and methods of use AMGEN INC. (US) 2012-05-15 US disclosed
US-8178557-B2 Compounds and methods of use AMGEN INC. (US) 2012-05-15 US disclosed
US-8178557-B2 Compounds and methods of use AMGEN INC. (US) 2012-05-15 US disclosed
US-20090176774-A1 Compounds and methods of use AMGEN INC. (US) 2009-07-09 US disclosed
US-20090176774-A1 Compounds and methods of use AMGEN INC. (US) 2009-07-09 US disclosed
US-20090176774-A1 Compounds and methods of use AMGEN INC. (US) 2009-07-09 US disclosed
US-7435823-B2 Compounds and methods of use AMGEN INC. (US) 2008-10-14 US disclosed
US-7435823-B2 Compounds and methods of use AMGEN INC. (US) 2008-10-14 US disclosed
US-7435823-B2 Compounds and methods of use AMGEN INC. (US) 2008-10-14 US disclosed
US-20060241115-A1 Compounds and methods of use AMGEN INC. 2006-10-26 US disclosed
EP-1713484-A2 COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2006-10-25 EP disclosed
WO-2005070891-A2 COMPOUNDS AND METHODS OF USE AMGEN INC (US) 2005-08-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060241115-A1 Compounds and methods of use HGF, HGFAC, MET KDR 354/4885RET 138/4885RAF1 1183/4885
US-20090176774-A1 Compounds and methods of use HGF, HGFAC, MET KDR 354/4885RET 138/4885RAF1 1183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.